SOURCE: Exagen Diagnostics, Inc.

August 23, 2006 11:44 ET

Exagen Diagnostics Adds Marketing Director

AUSTIN, TX -- (MARKET WIRE) -- August 23, 2006 -- Exagen Diagnostics, Inc., which develops and commercializes genomic marker-based in vitro diagnostic (IVD) kits for predicting risk of recurrence or treatment response, today announced that it has hired Richard Hockins, M.S., MBA, as a marketing director.

Hockins comes to his Austin-based role with Exagen from Roche Diagnostics where he held various commercial-based positions within sales of immunology and hematology, services marketing as well as product management for tumor, anemia, and infectious disease product lines. He has also worked as a sales and technical representative for both Gen-Probe and U.S. Pharmaceutical Corporation. Hockins is responsible for the launch of Exagen's first commercialized product, which is to be used in the prediction of breast cancer recurrence. He has a critical role in leading future Exagen products through FDA submission and developing educational materials and programs for physicians and laboratories.

About Exagen Diagnostics, Inc.

An emerging leader in the development of predictive in vitro diagnostic (IVD) kits, Exagen is uniquely able to discover, validate and productize small sets of genomic markers for use in oncology, infectious disease and other indications. The company's first tests predict the risk of breast cancer recurrence, so that women with a low or elevated risk of recurrence can be identified with high accuracy. Exagen plans to submit its first test to the Food and Drug Administration for clearance later this year, and will be the first to market a set of genomic markers to predict breast cancer recurrence using a fluorescent in situ hybridization (FISH) kit. For more information, visit

Contact Information